12:00 AM
Aug 27, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Xgeva regulatory update

The U.K.'s NICE issued a final appraisal determination (FAD) recommending the use of Xgeva denosumab from Amgen to prevent skeletal-related events (SREs) in patients with bone metastases from breast cancer; and in patients with bone metastases from solid tumors other than breast and prostate cancer for whom zoledronic acid would be indicated. The recommendation, which is contingent on Amgen providing Xgeva at an undisclosed discount under a patient access scheme, does not recommend Xgeva to prevent...

Read the full 358 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >